The Indian Journal of Pediatrics

, Volume 68, Issue 7, pp 635–639 | Cite as

Antiviral therapy: Respiratory infections, chornic hepatitis

Symposium on Antimicrobials—I
  • 34 Downloads

Abstract

This review focuses on the activity, clinical pharmacology, and clinical indications of antiviral agents used in the management of influenza, respiratory syncytial virus infections, and chronic hepatitis B and C. Two neuraminidase inhibitors, a new class of antiviral agents, were recently approved for the treatment of influenza A and B in children.

Key words

Antiviral agents Virus infections Neuraminidase inhibitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burlington DB, Meiklejohn G, Mostow SR. Anti-influenza A virus activity of amantadine hydrochloride and rimantadine hydrochloride in ferret tracheal ciliated epithelium.Antimicrob Agents Chemother 1982; 21 (5): 794–799.PubMedGoogle Scholar
  2. 2.
    Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity.Cell 1992; 69 (3): 517–528.PubMedCrossRefGoogle Scholar
  3. 3.
    Capparelli EV, Stevens RC, Chow MS, Izard M, Wills RJ. Rimantadine pharmacokinetice in healthy subjects and patients with end-stage renal failure.Clin Pharmacol Ther 1988; 43 (5): 536–541.PubMedCrossRefGoogle Scholar
  4. 4.
    Horadam VW, Sharp JG, Smilack JD,et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function.Ann Intern Med 1981; 94 (4 pt 1): 454–458.PubMedGoogle Scholar
  5. 5.
    Dougals RC Jr. Prophylaxis and treatment of influenza.N Engl J Med 1990; 322 (7): 443–450.CrossRefGoogle Scholar
  6. 6.
    Report of the committee of infectious diseases. 25th Edition. American Academy of Pediatrics, Elk Grove Village, IL 2000.Google Scholar
  7. 7.
    Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr. Successful treatment of naturally occurring influenza A/USSR/77 H1N1.JAMA 1981; 245 (11): 1128–1131.PubMedCrossRefGoogle Scholar
  8. 8.
    Hall CB, Dolin R, Gala CLet al. Children with influenza A infection: treatment with rimantadine.Pediatr 1987; 80 (2): 275–282.Google Scholar
  9. 9.
    Prober CG. Antiviral agents and interferons. In Long SS, Pickering, LK, Prober CG, eds.Principles and Practice of Pediatric Infectious Diseases. New York; Churchill Livingstone. 1997; 1682–1697.Google Scholar
  10. 10.
    Pimentel L, Hughes B. Amantadine toxicity presenting with complex ventricular ectopy and hallucinations.Pediatr Emerg Care 1991; 89–92.Google Scholar
  11. 11.
    Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.N Engl J Med 1989; 321 (25): 1696–1702.PubMedCrossRefGoogle Scholar
  12. 12.
    Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors.Lancet 2000; 355 (9206): 827–835.PubMedCrossRefGoogle Scholar
  13. 13.
    Varghese JN, Colman PM. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution.J Mol Biol 1991: 221 (2): 473–486.PubMedCrossRefGoogle Scholar
  14. 14.
    Montalto NJ, Gum KD, Ashley JV. Updated treatment for influenza A and B.Am Fam Physician 2000 62 (11): 2467–2476.PubMedGoogle Scholar
  15. 15.
    Treanor JJ, Hayden FG, Vrooman PS. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.JAMA 2000; 283 (8): 1016–1024.PubMedCrossRefGoogle Scholar
  16. 16.
    Blick TJ, Tiong T, Sahasrabudhe Aet al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.Virology 1995; 214 (2): 475–484.PubMedCrossRefGoogle Scholar
  17. 17.
    Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin.Antimicrob Agents Chemother. 1986; 30 (2): 201–205.PubMedGoogle Scholar
  18. 18.
    Connor E, Morrison S, Lane Jet al. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.Antimicrob Agents Chemother 1993; (3): 532–539.Google Scholar
  19. 19.
    Laskin OL, Longstreth JA, Hart CCet al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.Clin Pharmacol Ther 1987; 41 (5): 546–555.PubMedCrossRefGoogle Scholar
  20. 20.
    Hall CB, McBride JT, Walsh EEet al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.N Engl J Med 1983; 308 (24): 1443–1447.PubMedCrossRefGoogle Scholar
  21. 21.
    American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytical virus infections.Pediatr 1996; 97 (1): 137–140.Google Scholar
  22. 22.
    Wendt CH, Weisdort DJ, Jordan MC, Balfour HH Jr, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation.N Engl J Med 1992 2; 326 (14): 921–926.CrossRefGoogle Scholar
  23. 23.
    McCarthy AJ, Bergin M, De Silva LM, Stevens M. Intravenous ribavirin therapy for disseminated adenovirus infection.Pediatr Infect Dis J 1995 Nov; 14 (11): 1003–1004.PubMedCrossRefGoogle Scholar
  24. 24.
    Davis GL. Treatment of chronic hepatitis C: impact of combination therapy.Curr Gastroenterol Rep 1999; 1 (1): 9–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Huggins JW, Hsiang CM, Cosgriff TMet al. Prospective, double-blind, concurrent, placebocontrolled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome.J Infect Dis 1991; 164 (6): 1119–1127.PubMedGoogle Scholar
  26. 26.
    McCormick JB, King IJ, Webb PAet al. Lassa fever. Effective therapy with ribavirin.N Engl J Med 1986; 314 (1): 20–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Borden EC. Interferons: pleiotropic cellular modulators.Clin Immunol Immunopathol 1992; 62 (1 Pt 2): S18–24PubMedCrossRefGoogle Scholar
  28. 28.
    Wills RJ. Clinical pharmacokinetics of interferons.Clin Pharmacokinet 1990; 19 (5): 390–399.PubMedCrossRefGoogle Scholar
  29. 29.
    Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children.J Pediatr Gastroenterol Nutr. 1999; 29 (2): 163–170.PubMedCrossRefGoogle Scholar
  30. 30.
    Jonas MM. Interferon-alpha for viral hepatitis.J Pediatr Gastroenterol Nutr 1996; 23 (2): 93–106.PubMedCrossRefGoogle Scholar
  31. 31.
    Francavilla R, Mieli-Vergani G. Treatment of hepatitis C virus infection in children.Can J Gastroenterol 2000; 14 Suppl B: 41B-44B.PubMedGoogle Scholar
  32. 32.
    Heathcote J. Antiviral therapy for patients with chronic hepatitis C.Semin Liver Dis 2000; 20 (2): 185–199.PubMedCrossRefGoogle Scholar
  33. 33.
    Stentella P, Frega A, Di Renzi F, Palazzetti PL, Pachi A. Topic and systemic administration of natural alfa interferon in the treatment of female and male HPV genital infections.Clin Exp Obstet Gynecol 1996; 23 (1): 29–36.PubMedCrossRefGoogle Scholar
  34. 34.
    Healthcote EJ, Shiffman ML, Cooksley WGet al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.N Engl J Med 2000-7; 343 (23): 1673–1680.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2001

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Children’s Hospital of MichiganWayne State University, School of MedicineDetroitUSA

Personalised recommendations